Although the PIK3CA inhibitor alpelisib has been approved for the treatment of PIK3CA-mutated breast cancer [47], studies on head and neck cancer organoids demonstrate that its efficacy does not significantly correlate with PIK3CA mutation status, suggesting that tumor type may influence targeted drug sensitivity patterns [45]. Here, PIK3CA is linked to neoplasm.